Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 15 Issue 1, January 2019

Our January issue features articles on cancer cachexia, hypoxia-inducible factors in metabolic disease, the calcium-sensing receptor and the biology of PCSK9 beyond LDL control.

Image: Pancreatic islet image supplied by Shih-Jung Peng and Shiue-Cheng Tang at Department of Medical Science, National Tsing Hua University, Taiwan. Cover design: Jennie Vallis.

Research Highlights

Top of page ⤴

News & Views

  • In a longitudinal study that tracked BMI from early life, most children with obesity at age 3 years had overweight or obesity by adolescence. Of adolescents with obesity, ~50% were affected by overweight or obesity from age 5 years onwards, and the most rapid increase in BMI had occurred between 2 and 6 years of age.

    • Louise A. Baur
    • Sarah P. Garnett
    News & Views
  • Evidence for the predictive value of IADPSG/WHO2013 diagnostic gestational diabetes mellitus criteria for long-term maternal and offspring outcomes is missing. Recently, William L Lowe Jr and colleagues report a high risk of maternal glycaemic disorders and childhood adiposity 10 to 14 years after untreated gestational diabetes mellitus in the HAPO Follow-up Study.

    • Alexandra Kautzky-Willer
    • Jürgen Harreiter
    News & Views
Top of page ⤴


  • Cachexia is a multi-organ syndrome associated with cancer. In this Review, Josep M. Argilés and colleagues discuss the role of different tissues and organs in cancer cachexia and examine studies that investigate the development of novel therapeutics for the condition.

    • Josep M. Argilés
    • Britta Stemmler
    • Silvia Busquets
    Review Article
  • This Review focuses on the function of hypoxia-inducible factors (HIFs) in controlling metabolism and their influence in metabolic diseases (including obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease). The therapeutic potential of targeting HIFs for the treatment of metabolic diseases will also be discussed.

    • Frank J. Gonzalez
    • Cen Xie
    • Changtao Jiang
    Review Article
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors prevent cardiovascular events by lowering levels of LDL cholesterol derived from the liver. However, PCSK9 is expressed in many other tissues, including the pancreas and central nervous system. This Review explores the functions of PCSK9 beyond the control of cholesterol levels.

    • Robert M. Stoekenbroek
    • Gilles Lambert
    • G. Kees Hovingh
    Review Article
Top of page ⤴


Quick links